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The management of cough in adults with respiratory and non-respiratory illnesses is suboptimal
and based mostly on clinical opinions rather than evidence. A systematic review was carried
out assessing all trials in adult patients with respiratory and non-respiratory diseases
(excluding cancer) that had chronic cough as primary or secondary outcome. A total of 1177
trials were retrieved and 75 met the criteria for inclusion in the review. The vast majority were
in patients with asthma and chronic obstructive pulmonary disease (COPD). Cough was the
primary outcome in less than one-quarter of the studies. The measurement of cough was vari-
able, mostly using unvalidated scales or being part of an overall ‘symptoms’ score. Positive
results were overall seen with the use of corticosteroids, leukotriene receptor antagonists,
mast cell stabilizers, ipratropium bromide, neltenexine, iodinised glycerol and lidocaine.
Speech pathology training and symptom monitoring through SMS messages (accompanied by
treatment adjustments) have also shown promise. Evidence for established anti-tussive agents
such as codeine was scarce, with positive studies from the 1960s, whilst more recent studies
showed no effect in patients with COPD. Many studies had conflicting results. It is imperative
that the management of cough and its evidence base be improved, using higher quality
research designs and with cough being the primary outcome of trials.
ª 2010 Elsevier Ltd. All rights reserved.61 3067830; fax: þ44 161 306.
anchester.ac.uk (A. Molassiotis).
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Cough is a common symptom in respiratory (non-malignant)
diseases1 and related non-respiratory conditions, such as
nasal disease or gastro-oesophageal reflux disease (GORD/
GERD)]. Cough may either be productive (wet) producing
purulent or mucoid sputum or non-productive (dry). Cough
can be further divided into three categories based on dura-
tion: acute, lasting less than three weeks; sub-acute, lasting
three to eight weeks; and chronic, lasting more than eight
weeks.2,3 Common causes of non-malignant cough include
viral upper respiratory tract infections (the commonest by
far), airway disease, including asthma and chronic obstruc-
tive pulmonary disease; gastro-oesophageal reflux disease
(GORD), nasal disease, bronchiectasis and chronic infec-
tions. Persistent cough can be distressing to patients, leading
to depression (in up to 53% of patients),4,5 insomnia, vom-
iting, exhaustion and rib fractures.6,7 Cough has a significant
human and socioeconomic burden, as it is linked with
absenteeism from work, impaired quality of life and effects
in daily activities.8 A number of reviews outlining manage-
ment options1e3,8,9 exist, but there is limited comprehensive
systematic synthesis and assessment of effective manage-
ment strategies currently available in adult patients, as most
systematic reviews (a significant number being Cochrane
reviews) are focusing on children, whooping cough or anti-
biotic use in adults with prolonged cough. Furthermore, the
management of cough is highly variable in clinical practice,
and some of the reasons for this may include the unsystem-
atic evaluation of causes of cough, the frequent use of non-
specific cough treatments and the clinicians’ insufficient
knowledge in cough management.10 A synthesis of evidence
could assist in addressing some of these issues.Hence there is a need to examine the existing evidence
in cough research in respiratory and non-respiratory
illnesses in order to highlight areas needing further
research development, provide an understanding of the
level of evidence for interventions used to manage cough
and aid clinicians in their clinical decision-making.
Objective
The objective of this review was to determine the effec-
tiveness of pharmacological and non-pharmacological/non-
invasive interventions in the relief of cough in non-
malignant respiratory and non-respiratory conditions in
adult patients experiencing chronic cough.
Types of studies
Randomised Controlled Trials (with blinding)
Controlled Clinical Trials (quasi randomised trials, trials
with or without blinding and randomisation not
mentioned, trials with a comparative arm).
Types of participants
Adult patients described as experiencing either acute, sub-
acute or chronic cough; presence of cough (either produc-
tive (wet) cough producing purulent or mucoid sputum or
non-productive (dry) cough without purulent or mucoid
sputum) due to non-malignant respiratory and non-
respiratory diseases with a high prevalence of cough,
including interstitial lung disease (ILD), bronchiectasis;
Chronic Obstructive Pulmonary Disease (COPD)/Chronic
Obstructive Airways Disease (COAD); pulmonary oedema;
936 A. Molassiotis et al.lung abscess; emphysema; asthma; bronchitis; cardiac
disease, including congestive heart failure (CHF), chronic
heart failure and dilated cardiomyopathy; extra thoracic
causes of cough including reflux disease, nasal disease and
Ace-inhibitor related cough. Patients included in the
studies could be treated in any clinical setting. Interven-
tions should have a comparator group (placebo, another
substance or usual care). Studies designed to examine
effects on cough directly or as a proxy for improvement of
an underlying disorder would be included.
Exclusion criteria
The following disease types were excluded:
Upper respiratory tract infection e bacterial and viral/
chest infections; common cold; post infection cough,
habitual cough; enlarged uvula; stress; acute sinusitis, lung
cancer. Cough reflex sensitivity studies and animal studies
were also excluded. Paediatric studies were also excluded,
unless there was a mixed sample of children and adults.
Types of intervention
Pharmacological interventions: Any medicinal product or
substance as classified by the EU directive 2001/83/EEC
‘‘any substance or combination of substances which may be
administered to human beings or animals with a view to
making a diagnosis or to restoring, correcting or modifying
physiological function in human beings or animals is like-
wise considered a medicinal product.’’
Non-pharmacological interventions were defined
according to EU Directive 2001/83/EEC as ‘any interven-
tions that are not classified as medicinal products’ and
invasive and non-invasive interventions, such as comple-
mentary therapies, physiotherapy, education, behavioural
approaches and self-management.
Types of outcome measures
The primary outcome was subjective measures of cough
frequency, severity or distress on validated and reliable
scales such as visual analogue scales, numerical rating
scales, and categorical scales.
Secondary outcomes: Objective improvement in cough;
Quality of life measured by validated and reliable instru-
ments; Side-effects; Patient withdrawal from trials.
Search methods for identification of studies
A scoping search using broad terms and several databases,
as well as consultation with clinicians contributed to the
development of the search terms for this review. The
electronic databases searched included:
MEDLINE (1966eApril 2009)
EMBASE (1980eApril 2009)
CINAHL (1980eApril 2009)
British Nursing Index (1985eApril 2009)
PsychINFO (1985eApril 2009)
Science Citation Index Expanded (1985eApril 2009)AMED (Allied and Complementary Medicine) (1985eApril
2009)
Cochrane Pain, Palliative and Supportive Care Trails
Register (Winter 2009 issue) Cochrane Database of
Systematic Reviews (CDSR) (Winter 2009 issue)
The Cochrane Central Register of Controlled Trials
(CENTRAL) (Winter 2009 issue)
Database of Abstracts of Reviews of Effectiveness (DARE)
(Winter 2009 issue)
PEDRO (physiotherapy) database (to April 2009)
The Index to Scientific and Technical Proceedings (to
January 2009)
Conference Papers Index (to April 2009)
National Research Register (to April 2009)
SIGLE (System for Information on Grey Literature)
(1980eApril 2009)
Search strategy
The search terms included cough, respiratory illnesses (as
a general term and with specific diagnoses), generic classes
of drugs (anti-tussives, cough suppressants, opioids, topical
anaesthetics, NMDA receptor antagonists, antihistamines,
bronchodilators, steroids, antimuscarinics, aromatic inha-
lations) followed by specific drugs identified in the scoping
exercise, complementary therapies (with individual thera-
pies also included), physiotherapy, exercise movement
technique, self-management, self-care, respiratory
therapy, non-pharmacological interventions. In total, 108
terms were combined together with cough and respiratory
disease diagnoses alongside with a published strategy for
identifying randomised controlled trials.11 A complete
search strategy is available from the authors.
Hand searching, grey literature and personal
contact
The reference lists of all relevant studies were checked for
further relevant studies. Authors of main studies were
contacted to find out about any unpublished or grey liter-
ature. The Index to Scientific and Technical Proceedings,
the Conference Papers index and the National Research
Register were additionally searched for grey literature.
Language
Studies in English language or with an available English
translation were included.
Methods of the review
Selection of studies
Titles and abstracts of identified studies were reviewed for
relevance by two reviewers. The full text of all potentially
relevant studies was assessed by two reviewers. Any
disagreements were resolved after discussion with the rest
of the reviewing team.
Assessment of methodological quality
Methodological quality was assessed independently by two
reviewers. A Jadad score (Oxford Quality Index) was assigned
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assigned for randomisation, blinding and withdrawals/drop-
outs, with a higher score representing a higher quality trial.
Data extraction
A data extraction form was designed. One reviewer
extracted the data from each paper, and a second reviewer
evaluated the data extracted from all papers, reaching
agreement in relation to the quality of the data and the
Jadad score assigned. Agreement was achieved with each
assessor assessing a small number of papers independently
and then comparing the data extraction and scores with the
other assessor, discussing also ways of being consistent in
data extraction. A third reviewer checked a random sample
for consistency. The following details were included:
Publication details; Study aim; Study design; Sample size
and patient characteristics; Adverse events; Method of
assessing cough; Type of intervention; Outcome measures;
Withdrawals and dropouts; Handling of missing data; Study
results; Follow-up data; Any economic data; and any
patient narrative comments.
Data analysis
Reviewed studies were grouped into disease types and the
effectiveness of specific strategies within each disease
population assessed. A narrative synthesis is used to
analyse the data obtained.
Results
1177 articles were retrieved and assessed through the search
strategy. These included primarily results from searches in
the electronic databases (nZ 1164; 62 included) as well as
31 articles from hand searches (9 included) and 10 from
additional sources (4 included). Approaching key authors in
the field has resulted in no more articles. After excluding
duplicates, articles related to acute chest infections,
vaccines, malignancies, reviews and those which had no
outcome related to cough, 75 trials were included in this
review (see Table 1 for indicative studies and Online Table
under Supplementary Material for detailed description of all
studies reviewed).13e86
The 75 trials included in the review had a total sample of
11,738 adult patients (mean of 156 patients/trial), however
if the very large single trial63 on smoking cessation is
excluded (as it skews the results), the mean sample per
trial was 78 subjects, ranging from 8 to 5887 subjects. The
majority of studies were conducted in adult patients with
asthma and COPD patients.
Twenty-three trials were identified in adult patients
with asthma (n Z 1508, mean sample size Z 65, range
8e235). Steroids were the most common drug tested as a
cough therapy, and all studies were positive, particularly
with beclomethasone15,16,18,20 and budesonide.30 Mast cell
stabilizers were also shown to be effective, including
disodium cromoglycate,24 lodoxadine87 and nedocromil
sodium (two trials with positive results26,28) and two larger
trials with negative results.27,29 Leukotriene receptor
antagonists were also effective (2 trials) as was the use of
a Th2 cytokine inhibitor (1 trial).25,32,35 Two different
ayuverdic herbs were equally effective with salbutamol and
deriphylline used in one trial,33 although the trial was ofpoor quality, as was another positive herbal trial using
ginger.19 Theophylline did not show any improvements in
cough in one trial.34 A study whereby patients reported PEF
values to researchers daily through SMS messages and
researchers subsequently contacted patients to adjust
medication or arrange hospital appointments showed
significantly lower cough scores than the control group in
a small study of 16 patients.31
Eight trials were identified in relation to adult patients
with bronchitis (totalnZ 731). All but two trials had a sample
size of less than 80 subjects. While the use of low dose N-
acetylcysteine38,39 and budenoside40 were negative, effec-
tive treatments included epinastine,41 ipratropium bromide
over fenspiride42 theophylline45 and iodinised glycerol.43,44
Eighteen trials included adult patients with COPD
(n Z 8013 subjects), with a mean of 125 subjects/trial
(excluding the single very large smoking cessation trial).
Negative studies included the use of budesonide,47
codeine,48 nesosteine61 and oxitropium bromide (in addi-
tion to theophylline).62 Positive results were shown with
regards to fenspiride,50 fluticasone,51 formoterol,52 nelte-
nexine,58e60 helicidine (a biological extract prepared from
the snail Helix pomatia L.),53 oxtriphylline64 and a high dose
(1200 mg) N-acetylcysteine.56 While lidocaine 4 ml had an
equivalent effect to bronchodilators (but fewer side-
effects)55 and ipratropium bromide was also equivalent to
another drug of the same class, that of metaproterenol.54
In a large trial of 5887 smokers, a smoking cessation pro-
gramme led to significant decreases in cough symptoms as
well as in the use of inhaled ipratropium bromide.63
Five trials have tested a proton pump inhibitor in the
management of cough in adult patients with reflux disease
(n Z 258 subjects; mean of 52 patients/trial). While eso-
prazole and omeprazole showed negative results in one
trial each,69,72 lansoprazole70 and omeprazole71,73 have
provided positive results over placebo. Morphine (5 mg) in
one trial66 and speech pathology training in another trial67
were also effective treatments in relation to idiopathic
cough. Allergic rhinoconjuctivitis was the focus of one trial
only, in which the tested antihistamine (loratadine) in
a small-scale study was shown to be effective.13 Benzona-
tate was equivalent to a mixture that contained codeine in
one trial of patients with asthmatic bronchitis and emphy-
sema36 as was codeine in a small trial of 10 patients.68
Moguisteine and dextromethophran were shown to be
equivalent in a trial of 124 patients.78 A large trial of
codeine was also effective in a dose of 60 mg46 as was
neltenexine in two further trials.79,80 Sinecod linctus,
a common over-the-counter cough medication, was no
more effective than a small dose of codeine in one trial.86
Discussion
Some of the key and overarching issues identified through
this systematic review include the limited amount of
research directed specifically to the management of
chronic cough, the significant quality and methodological
issues that exist with various studies, and the small samples
used. Among the 75 studies reviewed, only about one-
quarter (N Z 20) of the studies used ‘cough’ as a primary
outcome. The vast majority of studies were focused on
efficacy of treatment in relation to respiratory illnesses,
Table 1 Indicative interventions for non-malignant cough [for a description of all studies see Online Table under Supplementary material].
Author Date
Country
Study Design Sample, size Treatment (dose) Outcome Measures Results Conclusions/Comments Jadad
score
Ribeiro
et al.,
2007
Brazil18
RCT Double
Blind
N Z 64 (42M/22F) Chlorofluorocarbon-
beclomethasone
(1500 mg/d) or placebo
for 2 weeks.
Decrease in daily
cough scores during
the 2-week
treatment period
(Patient symptom,
diary and visual
analogue scale
(Primary)
36/42 patients (82%) in active group had
complete resolution of cough. 8 showed no
improvement (18%). Cough cessation was
observed in 3 patients (15%) in the placebo
group, whilst cough persisted in 17
patients (85%).
Significant improvement in
cough symptoms in patients
treated with
chlorofluorocarbon-
beclomethasone compared with
placebo.
4
Patients had
cough>8 weeks.
Secondary outcomes:
Duration of cough,
respiratory
questionnaire,
bronchoprovocation
testing (BPT) with
methaholine and
allergy testing
Median duration of cough similar in both
groups (P Z 0.9). Difference in cough
diaries and VAS before and after
beclomethasone compared with before
and after placebo (difference of
differences, 1.0 95% CI, 0.4e1.5; P < 0.002
for diaries, difference of differences 1.1,
95% CI 0.6e1.8, P < 0.01 for VAS).
Comparison of symptom diaries with VAS
data for the placebo and control groups at
the end of the protocol (P Z 0.001)
Significant difference in
numbers of patients
experiencing resolution of
cough when treated with
chlorofluorocarbon-
beclomethasone compared to
placebo.
10 patients were
smokers.
No correlation between cough diaries and
questionnaires (rZ 0.12, PZ 0.07) or BPT
(r Z 0.23, P Z 0.06).
Nicolis
et al.,
1962
Italy46
RCT Double
Blind
N Z 184
(No gender info)
Study 1: Codeine (30mg
qid) or placebo for 5
days, crossed over after
a 3 day washout period
(n Z 43).
Cough (primary) Study 1 and 2 failed to show any significant
difference between placebo and codeine.
Statistically significant
difference in number of coughs
in patients treated with a single
dose of codeine (60mg)
compared to placebo. However,
2 studies with lower codeine
dosages over longer timeframe
failed to identify a significant
effect on cough.
2
N Z 19 (14M/5F) Study 2: Codeine (30mg
qid) or placebo for 8
days crossed over every
3 days (n Z 56)
Study 3 reported a significant difference in
number of coughs in patients treated with
codeine compared to placebo (group 1:
6.4  1.2 V 11.7  1.5, P < 0.001; group 2:
8.2  1.9 V 13.5  1.9, P < 0.001; Group 3:
9.8  1.6 VS. 14.5  1.9, P < 0.001).
Authors give no information
about withdrawals or adverse
events.
Study 3: Codeine (60mg)
or placebo single
application. (3 separate
groups of patients).
Authors also provide a graphical
comparison of mean number of coughs/h
at 3 different time-points for 33 patients
(group3). Difference between codeine and
placebo significant at 3 h and 4 h after
codeine administration 2 h after
administration Z P > 0.05, 3 h after
administration Z P < 0.01, 4 h after
administration Z P < 0.001).
Trend towards difference in the mean
number of coughs in heavier coughing
patients treated with codeine (NS).
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Smith et al.,
2006 UK48
RCT Double
blind, placebo
controlled
Cross-over
trial
N Z 19 (14M/5F) Codeine (60 mg b.i.d.)
or placebo.
Cough frequency
(primary)
Citric acid
thresholds,
subjective cough
measures (VAS).
Median rate of cough (combined night and
day scores) was lower during treatment
with codeine (6.41 coughs/h, IQR 3.86e
9.10, P Z 0.02 compared with baseline)
compared to placebo (7.22 c/h, IQR 4.42e
10.40, P Z 0.03 compared with baseline)
and baseline (8.27 c/h, IQR 5.94e11.67).
4% reduction in cough rate was observed
for codeine compared with placebo (mean
difference Z 1.1 cs/h, 95% CI, 0.89e
1.25 cs/h).
No significant improvement in
cough frequency in patients
treated with codeine compared
to placebo.
4
Log 10 transformed cough rates showed a
sig. difference between baseline, placebo
and codeine rates (repeat-measures
ANOVA, F Z 4.97, df Z 2, P Z 0.02).
Differences between baseline, codeine
and placebo treatments was seen in day
cough scores 9fZ 3.72, dfZ 2, PZ 0.05),
but not in night scores (F Z 0.56, df Z 2,
P0.48). Difference between subjective
baseline cough scores and day and night
scores NS (F Z 0.453, df Z 2, P Z 0.59;
and F Z 0.68, df Z 2, P Z 0.50
respectively).
No SD between daytime codeine and
baseline VAS scores P Z 0.11. Difference
between codeine and placebo, P Z 0.96.
No SD between baseline, placebo or
codeine (P Z 0.25). No significant
correlations between the change in time
spent coughing and the change in cough
score (day r Z 0.07, P Z 0.78,
night Z 0.17, P Z 0.48) or change in VAS
(day rZ 0.07, PZ 0.79, night rZ 0.30,
P Z 0.24).
Chong
et al.,
2005
Taiwan55
RCT Double
blind
N Z 127 (85M/42F) Lidocaine (4 ml N Z 62)
or Bronchodilator
(N Z 65)
Effectiveness
(primary)
Improvement in cough severity scores in
both groups 1 h post inhalation compared
to baseline (Lidocaine score Z 3 versus 8,
P < 0.01, Bronchodilator score Z 3 versus
8, P < 0.01.). P Z 0.44 for difference
between Lidocaine and bronchodilators.
Significant improvement in
cough severity scores in
patients treated with Lidocaine
or Bronchodilators for short
term cough suppression.
5
Cough severity score,
comparison of
adverse effects.
228 adverse events reported.
Significantly more patients
experienced tremors and
palitations whilst using
Bronchodilators compared to
those Lidocaine. Significantly
more patients using lidocaine
reported oropharyngeal
numbness and a bitter taste
compared to bronchodilator
patients (P < 0.01).
(continued on next page)
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940 A. Molassiotis et al.with cough being a secondary outcome. Very few studies
reported sample size calculations, hence it is not possible
to ascertain whether negative results are due to a Type II
error or not. Quality scores were also variable, although it is
encouraging to see that more recent studies have been
assigned higher Jadad scores in this review.
The measurement of cough in the reviewed studies has
been particularly problematic. The vast majority of the
trials have used patient diaries, cough counts, and patient
self reports, largely unvalidated methods for measuring
cough. Often cough has been only a small component of
‘symptoms’ and included as part of a number of other
symptoms (such as dyspnoea) assessed together. Only
a couple of trials have used a validated method of
measuring cough, such as the Leicester Cough Question-
naire. Some studies assessed cough frequency, some others
cough intensity and others cough distress/discomfort.
While these data are important, each study describes
a separate facet of the cough symptom experience:
a better approach, arguably, would be to address all three
parameters together as each provides a different and
complementary perspective (a frequent mild and not dis-
tressing cough is a different experience, for example,
compared with an occasional severe and distressing cough).
Nevertheless, some treatments have shown consistently
positive results (with varying levels of effect) in specific
patient groups, including corticosteroids, leukotriene
receptor antagonists, mast cell stabilizers, ipratropium
bromide, neltenexine, ionised glycerol and lidocaine. In
GORD, proton pump inhibitors may be effective in individual
patients, but a relevant systematic review specific to GORD
suggests that data are insufficient to support their use,88
while for allergic rhinoconjuctivitis the use of antihista-
mines may be appropriate. The trials, however, often present
mixed results that do not allow for firm conclusions to be
drawn (such as the mast cell stabilizer nedocromil) or positive
evidence comes from a single small study with no replication
(such as Th2 cytokine inhibitor). Also, the example of codeine
(by far one of the commonest prescriptions for cough) is
interesting as it is generally considered to be the anti-tussive
to which novel treatments should be compared. Early small
scale and poor quality trials in the 1960s/70s show positive
results, while more recent higher quality trials suggest no
effect of codeine over placebo; whether codeine should be
the comparator when designing trials of new medications is
increasingly in question. Benzonatate, moguisteine and
dextromethophran (the latter often included in over-the-
counter cough mixtures) also showed possible effects, but
again the evidence base for these drugs is small.
Non-pharmacological trials are scarce, with only three
trials identified, and only two (speech pathology training and
use of SMS messages to monitor symptoms) showing positive
results. Speech pathology training could be a useful adjunct
to pharmacological treatments, particularly as coughing has
the potential to traumatise the upper airways (i.e. the vocal
cords). More work should be directed in this promising area.
Monitoring symptoms through technology (mobile phones/
internet) is another area that has shown improvements, and
this is a method that can have important self-management
and health service utilisation implications. This is an area of
increasing research focus, and studies have already started
demonstrating the potential of such applications.89,90
Pharmacological and non-pharmacological interventions for cough in adults 941It is clear that the treatment options for cough are far
from satisfactory, and have been described as an unmet need
for the cough patient.91 Future research should focus more
appropriately in providing concrete evidence for the
management of this common and distressing symptom.
Cough should be measured as the primary outcome with the
use of validated methods that consider all dimensions of the
cough experience. Both subjective and objective measures
should be used, as they have the potential to capture both
patient perception and independent evidence of efficacy.92
Patients should be selected carefully for inclusion, avoiding
heterogeneity in terms of concurrent respiratory disease,
smoking status and other clinical characteristics that may
affect the results (i.e. concurrent maintenance treatments).
More research should explore the impact of cough on
psychosocial status, quality of life and daily activities. Also,
it is unclear from the trials reviewed what the duration of any
treatment should be, as studies for the same drug have used
different durations for the intervention. Many of the studies
showing statistically significant positive effects have
managed to change the cough by 15e20%; whether this is
a clinically important difference and whether patients can
notice such a small difference is unclear. This issue needs
further exploration in the literature. There should also be
a better balance between testing non-specific and specific
anti-tussives in the future.
With the lack of clarity in the assessment and manage-
ment of cough as described above and elsewhere,91,93 it is
not surprising that clinical guidelines have focused to date
more on principles of treatment rather than on much
needed explicit guidance for clinical decision-making, and
are mostly based upon expert opinion rather than evidence
base. Such difficulties have been highlighted in the latest
updated guidelines from the American College of Chest
Physicians.92
Idiopathic cough, accounting for a significant number of
patients seen in secondary and tertiary care, has been the
focus of only 3 trials with a total of 158 subjects enrolled. A
20% of patients with cough may present with more than one
aggravating factor,94 and this group of patients may need
a more complex management regime before symptom
resolution is achieved, but few trials have focused on this
population. Combinations of treatments may need to be
developed, including both pharmacological and non-
pharmacological approaches. Furthermore, there is an
urgent need for more high quality research to build the
evidence base around the management of cough in respi-
ratory illness, more attention from the physicians and
higher investment from the industry. New preparations are
in phase II or III trials (e.g. NOP1 agonists, bradykinin B2 or
GABA receptor antagonists, among others).93 Amitryptiline,
gabapentin and carbamazepine are experimental options
that could have a role in the management of cough91 sup-
ported by case study reports. It is to be hoped that some
better tested and improved cough medications will enter
the market in the next few years.Conflict of interest statement
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